Bevacizumab to combat EGFR-TKI resistance in a patient with advanced non-small cell lung cancer harboring an EGFR mutation: A case report.
about
Bevacizumab to combat EGFR-TKI resistance in a patient with advanced non-small cell lung cancer harboring an EGFR mutation: A case report.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bevacizumab to combat EGFR-TKI ...... EGFR mutation: A case report.
@en
Bevacizumab to combat EGFR-TKI ...... EGFR mutation: A case report.
@nl
type
label
Bevacizumab to combat EGFR-TKI ...... EGFR mutation: A case report.
@en
Bevacizumab to combat EGFR-TKI ...... EGFR mutation: A case report.
@nl
prefLabel
Bevacizumab to combat EGFR-TKI ...... EGFR mutation: A case report.
@en
Bevacizumab to combat EGFR-TKI ...... EGFR mutation: A case report.
@nl
P2093
P2860
P356
P1433
P1476
Bevacizumab to combat EGFR-TKI ...... EGFR mutation: A case report.
@en
P2093
P2860
P304
P356
10.3892/OL.2016.4574
P577
2016-05-16T00:00:00Z